FeRx reports on cancer Phase I/II

FeRx (San Diego, Calif.) said its MTC-DOX iron-carbon drug delivery system with doxorubicin was safe and well tolerated in a 16-patient Phase I/II trial to treat primary liver cancer. Data were presen...